These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21807817)

  • 1. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
    Zagon IS; Porterfield NK; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
    McLaughlin PJ; Rogosnitzky M; Zagon IS
    Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
    Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
    Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
    Zagon IS; Donahue RN; McLaughlin PJ
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Donahue RN; McLaughlin PJ; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
    Kren NP; Zagon IS; McLaughlin PJ
    Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and differentiation in human cancer cells.
    Zagon IS; McLaughlin PJ
    Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
    Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
    J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.